Selumetinib in the Treatment of Symptomatic Intractable Plexiform Neurofibromas in Neurofibromatosis Type 1: A Prospective Case Series with Emphasis on Side Effects

Paediatric Drugs
Francesco BaldoEgidio Barbi

Abstract

Plexiform neurofibromas (PN) are congenital tumors that affect up to 50% of individuals with neurofibromatosis type 1. Despite their benign nature, they can grow rapidly and cause severe morbidities. Selumetinib, an inhibitor of mitogen-activated protein kinase (MEK) 1 and 2, was reported to induce a clinical response in pediatric subjects with inoperable PN. The aim of this paper is to describe a prospective case series of patients treated with selumetinib with emphasis on drug adverse events. All the subjects who received selumetinib at the Pediatric Department of Scientific Research Institute and Hospital "Burlo Garofolo", from November 2017 to January 2020, were progressively included. We monitored the patients with a follow-up visit every 3 months. MRI or CT scans to monitor the growth of the tumor were performed after 3 months of treatment, and then every 6-9 months. Selumetinib was prescribed to nine children, with a total of 17 inoperable PN. The mean follow-up period was 12 months. During the follow-up, one patient experienced an ischemic stroke, unrelated to the treatment. Only minor adverse events were observed: six individuals developed gastrointestinal side effects, seven patients presented a mild form of acne, six...Continue Reading

References

Jan 19, 2005·Archives of Dermatology·Marga LammertVictor F Mautner
Oct 6, 2012·Orphanet Journal of Rare Diseases·Rosa NguyenVictor-Felix Mautner
Aug 13, 2013·Handbook of Clinical Neurology·Rosalie E Ferner, David H Gutmann
Oct 22, 2015·Archives of Disease in Childhood. Education and Practice Edition·B M Dunning-Davies, A P J Parker
Dec 29, 2016·The New England Journal of Medicine·Eva DombiBrigitte C Widemann
Feb 24, 2017·Nature Reviews. Disease Primers·David H GutmannKimberly J Johnson
Sep 4, 2018·Ecancermedicalscience·Honoré PapaliaNicolas André
May 30, 2019·Neuropediatrics·Pia VaassenThorsten Rosenbaum
Feb 29, 2020·Journal of Neuro-oncology·Vera Espírito SantoSofia Nunes
Mar 19, 2020·The New England Journal of Medicine·Andrea M GrossBrigitte C Widemann

❮ Previous
Next ❯

Citations

Aug 21, 2021·Bioorganic & Medicinal Chemistry·Thais Cristina Mendonça Nogueira, Marcus Vinicius Nora de Souza

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

© 2022 Meta ULC. All rights reserved